Daniel S. Raccuia, PharmD candidate 2016
Daniel S. Raccuia is a 2016 PharmD candidate at University of Connecticut School of Pharmacy, Storrs, Conn.
FDA approves rolapitant to prevent chemotherapy-induced nausea and vomiting
Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.